Cargando…

Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy

BACKGROUND AND AIM: Helicobacter pylori eradication clearly decreases peptic ulcer recurrence rates. H. pylori eradication is achieved in 70–90% of cases, but treatment failures due to poor patient compliance and resistant organisms do occur. Lactobacillus gasseri can suppress both clarithromycin-su...

Descripción completa

Detalles Bibliográficos
Autores principales: Deguchi, Ryuzo, Nakaminami, Hidemasa, Rimbara, Emiko, Noguchi, Norihisa, Sasatsu, Masanori, Suzuki, Takayoshi, Matsushima, Masashi, Koike, Jun, Igarashi, Muneki, Ozawa, Hideki, Fukuda, Ryuki, Takagi, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Asia 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504346/
https://www.ncbi.nlm.nih.gov/pubmed/22098133
http://dx.doi.org/10.1111/j.1440-1746.2011.06985.x
_version_ 1782250615001317376
author Deguchi, Ryuzo
Nakaminami, Hidemasa
Rimbara, Emiko
Noguchi, Norihisa
Sasatsu, Masanori
Suzuki, Takayoshi
Matsushima, Masashi
Koike, Jun
Igarashi, Muneki
Ozawa, Hideki
Fukuda, Ryuki
Takagi, Atsushi
author_facet Deguchi, Ryuzo
Nakaminami, Hidemasa
Rimbara, Emiko
Noguchi, Norihisa
Sasatsu, Masanori
Suzuki, Takayoshi
Matsushima, Masashi
Koike, Jun
Igarashi, Muneki
Ozawa, Hideki
Fukuda, Ryuki
Takagi, Atsushi
author_sort Deguchi, Ryuzo
collection PubMed
description BACKGROUND AND AIM: Helicobacter pylori eradication clearly decreases peptic ulcer recurrence rates. H. pylori eradication is achieved in 70–90% of cases, but treatment failures due to poor patient compliance and resistant organisms do occur. Lactobacillus gasseri can suppress both clarithromycin-susceptible and -resistant strains of H. pylori in vitro. The aim of this study was to determine the effect of pretreatment with L. gasseri- containing yogurt on H. pylori eradication. We conducted a randomized, controlled clinical trial in patients with H. pylori infection. METHODS: A total of 229 patients were randomized into either a 1-week triple therapy of rabeprazole (10 mg bid), amoxicillin (750 mg bid), and clarithromycin (200 mg bid) or triple therapy plus L. gasseri-containing yogurt. In the yogurt-plus-triple therapy groups, yogurt containing L. gasseri OLL2716 (112 g) was given twice daily for 4 weeks (3 weeks pretreatment and also 1 week during eradication therapy). Clarithromycin resistance was determined by the detection of a mutation in 23S rRNA using nested polymerase chain reaction and the direct sequencing of DNA from pretreatment feces. H. pylori eradication was diagnosed based on the urea breath test and a stool antigen test after 8 weeks of eradication. RESULTS: The status of H. pylori susceptibility to clarithromycin was successively determined in 188 out of 229 samples. The rate of infection with clarithromycin-resistant strains of H. pylori was 27.1%. Overall eradication (intention to treat/per protocol) was 69.3/74.5% for the triple-only group, and 82.6/85.6% for the yogurt-plus-triple group (P = 0.018/P = 0.041). Eradication of primary clarithromycin-resistant strains tended to be higher for yogurt-plus-triple therapy than triple-only therapy (38.5 vs 28.0%, respectively, P = 0.458). CONCLUSION: This study confirmed that the major cause of treatment failure is resistance to clarithromycin. A 4-week treatment with L. gasseri-containing yogurt improves the efficacy of triple therapy in patients with H. pylori infection.
format Online
Article
Text
id pubmed-3504346
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Asia
record_format MEDLINE/PubMed
spelling pubmed-35043462012-11-30 Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy Deguchi, Ryuzo Nakaminami, Hidemasa Rimbara, Emiko Noguchi, Norihisa Sasatsu, Masanori Suzuki, Takayoshi Matsushima, Masashi Koike, Jun Igarashi, Muneki Ozawa, Hideki Fukuda, Ryuki Takagi, Atsushi J Gastroenterol Hepatol Clinical Trials and Therapeutics BACKGROUND AND AIM: Helicobacter pylori eradication clearly decreases peptic ulcer recurrence rates. H. pylori eradication is achieved in 70–90% of cases, but treatment failures due to poor patient compliance and resistant organisms do occur. Lactobacillus gasseri can suppress both clarithromycin-susceptible and -resistant strains of H. pylori in vitro. The aim of this study was to determine the effect of pretreatment with L. gasseri- containing yogurt on H. pylori eradication. We conducted a randomized, controlled clinical trial in patients with H. pylori infection. METHODS: A total of 229 patients were randomized into either a 1-week triple therapy of rabeprazole (10 mg bid), amoxicillin (750 mg bid), and clarithromycin (200 mg bid) or triple therapy plus L. gasseri-containing yogurt. In the yogurt-plus-triple therapy groups, yogurt containing L. gasseri OLL2716 (112 g) was given twice daily for 4 weeks (3 weeks pretreatment and also 1 week during eradication therapy). Clarithromycin resistance was determined by the detection of a mutation in 23S rRNA using nested polymerase chain reaction and the direct sequencing of DNA from pretreatment feces. H. pylori eradication was diagnosed based on the urea breath test and a stool antigen test after 8 weeks of eradication. RESULTS: The status of H. pylori susceptibility to clarithromycin was successively determined in 188 out of 229 samples. The rate of infection with clarithromycin-resistant strains of H. pylori was 27.1%. Overall eradication (intention to treat/per protocol) was 69.3/74.5% for the triple-only group, and 82.6/85.6% for the yogurt-plus-triple group (P = 0.018/P = 0.041). Eradication of primary clarithromycin-resistant strains tended to be higher for yogurt-plus-triple therapy than triple-only therapy (38.5 vs 28.0%, respectively, P = 0.458). CONCLUSION: This study confirmed that the major cause of treatment failure is resistance to clarithromycin. A 4-week treatment with L. gasseri-containing yogurt improves the efficacy of triple therapy in patients with H. pylori infection. Blackwell Publishing Asia 2012-05 /pmc/articles/PMC3504346/ /pubmed/22098133 http://dx.doi.org/10.1111/j.1440-1746.2011.06985.x Text en © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Clinical Trials and Therapeutics
Deguchi, Ryuzo
Nakaminami, Hidemasa
Rimbara, Emiko
Noguchi, Norihisa
Sasatsu, Masanori
Suzuki, Takayoshi
Matsushima, Masashi
Koike, Jun
Igarashi, Muneki
Ozawa, Hideki
Fukuda, Ryuki
Takagi, Atsushi
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
title Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
title_full Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
title_fullStr Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
title_full_unstemmed Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
title_short Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
title_sort effect of pretreatment with lactobacillus gasseri oll2716 on first-line helicobacter pylori eradication therapy
topic Clinical Trials and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504346/
https://www.ncbi.nlm.nih.gov/pubmed/22098133
http://dx.doi.org/10.1111/j.1440-1746.2011.06985.x
work_keys_str_mv AT deguchiryuzo effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT nakaminamihidemasa effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT rimbaraemiko effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT noguchinorihisa effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT sasatsumasanori effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT suzukitakayoshi effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT matsushimamasashi effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT koikejun effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT igarashimuneki effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT ozawahideki effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT fukudaryuki effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy
AT takagiatsushi effectofpretreatmentwithlactobacillusgasserioll2716onfirstlinehelicobacterpylorieradicationtherapy